Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile

Scandinavian Journal of Immunology

Volumn 64, Issue 5, 2006, Pages 554-563

  Sathler Avelar, R ^a,b   Vitelli Avelar, D M ^a   Massara, R L ^a   Borges, J D ^c   Lana, M ^c   Teixeira Carvalho, A ^a,c   Dias, J C P ^a   Eloi Santos S M ^a,b   Martins Filho, O A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BENZNIDAZOLE; CD19 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INNATE IMMUNITY; INTERFERON PRODUCTION; LEUKOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TRYPANOSOMA CRUZI;

ADOLESCENT; ANIMALS; CASE-CONTROL STUDIES; CHAGAS DISEASE; CHILD; CYTOKINES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNITY, INNATE; IMMUNITY, NATURAL; LONGITUDINAL STUDIES; MALE; NITROIMIDAZOLES; TRYPANOSOMA CRUZI;

EID: 33749541953     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01843.x     Document Type: Article

References (23)

1. Andrade ZA. Immunopathology of Chagas disease. Mem Inst Oswaldo Cruz 1999;94:71-80.
2. WHO. Expert Committee. Control of Chagas disease. World Health Organ Tech Rep 2002;905:1-109.
3. Dias JC. The indeterminate form of human chronic Chagas disease. A clinical epidemiological. Rev Soc Bras Med Trop 1989;22:147-56.
4. Brener Z, Gazzinelli RT. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas disease. Int Arch Allergy Immunol 1997;114:103-10.
5. Sathler-Avelar R, Lemos EM, Reis DD et al. Phenotypic features of peripheral blood leucocytes during early stages of human infection with Trypanosoma cruzi. Scand J Immunol 2003;8:655-63.
6. Zhang L, Tarleton RL. Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and Type 2 cytokine production. Eur J Immunol 1996;26:102-9.
7. Antunez MI, Cardoni RL. IL-12 and IFN-gamma production, and NK cell activity, in acute and chronic experimental Trypanosoma cruzi infections. Immunol Lett 2000;71:103-9.
8. Samudio M, Montenegro-James S, Cabral M, Martinez J, Rojas de Arias A, James MA. Cytokine responses in Trypanosoma cruzi-infected children in Paraguay. Am J Trop Med Hyg 1998;58:119-21.
9. Bahia-Oliveira LM, Gomes JA, Cancado JR et al. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J Infect Dis 2000;182:634-8.
10. Bahia-Oliveira LM, Gomes JA, Rocha MO et al. IFN-gamma in human Chagas' disease: protection or pathology? Braz J Med Biol Res 1998;31:127-31.
11. Luz ZM. Changes in the hemoculture methodology improve the test positivity. Mem Inst Oswaldo Cruz 1999;94:295-8.
12. Lowry OH, Rosenbrough M, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
13. Peruhype-Magalhaes V, Martins-Filho OA, Prata A et al. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 2005;62:487-95.
14. Aliberti JC, Cardoso MA, Martins GA, Gazzinelli RT, Vieira LQ, Silva JS. Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun 1996;64:1961-7.
15. Cardillo F, Voltarelli JC, Reed SG, Silva JS. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK-cells. Infect Immun 1996;64:128-34.
16. Camargo MM, Almeida IC, Pereira ME, Ferguson MA, Travassos LR, Gazzinelli RT. Glycosylphosphatidylinositol-anchored mucinlike glycoproteins isolated from Trypanosoma cruzi trypomastigotes initiate the synthesis of proinflammatory cytokines by macrophages. J Immunol 1997;158:5890-1.
17. Duthie MS, Wleklinski-Lee M, Smith S, Nakayama T, Taniguchi M, Kahn SJ. During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Infect Immun 2002;70:36-48.
18. Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997;114:91-9.
19. Molina J, Martins-Filho O, Brener Z, Romanha AJ, Loebenberg D, Urbina JA. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000;44:150-5.
20. Michimata T, Ogasawara MS, Tsuda H et al. Distributions of endometrial NK cells, B cells, T cells, and Th2/Tc2 cells fail to predict pregnancy outcome following recurrent abortion. Am J Reprod Immunol 2002;47:196-202.
21. Michimata T, Sakai M, Miyazaki S et al. Decrease of T-helper 2 and T-cytotoxic 2 cells at implantation sites occurs in unexplained recurrent spontaneous abortion with normal chromosomal content. Hum Reprod 2003;18:1523-8.
22. Lebrec H, Kerdine S, Gaspard I, Pallardy M. Th(1)/Th(2) responses to drugs. Toxicology 2001;158:25-9.
23. Noble A, Giorgini A, Leggat JA. Cytokine-induced IL-10-secreting CD8 T cells represent a phenotypically distinct suppressor T cell lineage. Blood 2006;107:4475-83.